Share on LinkedInShare on LinkedIn

ARTICLE · 04 JANUARY 2018

Canada's New Linkage Litigation Scheme: A Comparison To Hatch-Waxman

Smart & Biggar
Explore more from Smart & Biggar

The September 21, 2017 amendments to the Patented Medicines (Notice of Compliance) Regulations (see our article here) introduced a new scheme for pharmaceutical patent linkage litigation in Canada.

CanadaIntellectual Property
Nancy Pei
Nancy Pei
Author LinkedIn connections

The September 21, 2017 amendments to the Patented Medicines (Notice of Compliance) Regulations (see our article here) introduced a new scheme for pharmaceutical patent linkage litigation in Canada. That scheme is now much closer to the US Hatch-Waxman scheme, but with remaining key differences, as shown in the chart below. A special thank you to Brian Coggio of Fish & Richardson for contributing the Hatch-Waxman details.

View chart >>

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

View source

Related Articles

Read more about

Related Comparative Guides

See more popular content from

Article

A KTEP Ahead: Canada's New Mechanism For Advanced Examination Of Patent Applications

For a Canadian patent application to be examined, an applicant must file a request for examination with the Canadian Intellectual Property Office (CIPO). In most cases, the order in which applications are examined is based on the order that the requests for examination are received. An applicant may be able to accelerate examination of their patent application through several existing mechanisms, including advancing examination via special order, accelerating examination of applications related to green technology, and the Patent Prosecution Highway (PPH).
CanadaIntellectual Property
Smart & Biggar
Smart & Biggar
Article

Patenting Innovation In Data Centres: Protecting Configurations, Cooling Technologies, And The Green Advantage

The rapid expansion of data centre infrastructure has made these facilities a focal point for technological innovation and intellectual property investment. From server configurations to advanced cooling systems, the technologies deployed inside data centres represent significant R&D expenditure and competitive advantages. Patent protection offers operators and developers opportunities to safeguard innovations...
WorldwideIntellectual Property
Gowling WLG
Gowling WLG
Article

Recent TMOB Decision Shows That Sometimes, Establishing Use In A Section 45 Proceeding Is Straightforward

The Trademarks Opposition Board recently upheld a registration for the FRÜH & DESIGN trademark covering top fermented beers, demonstrating that clear evidence of use can successfully defend against section 45 proceedings. This decision illustrates how straightforward documentation of sales, distribution networks, and delivery records proved sufficient to maintain trademark protection in Canada.
CanadaIntellectual Property
Oyen Wiggs Green & Mutala
Oyen Wiggs Green & Mutala
Article

Understanding The Canadian Intellectual Property Office's Patent TermAdjustment (PTA) System

Canada's new Patent Term Adjustment system offers compensation for delays in patent issuance, but qualifying depends on meeting specific eligibility requirements and strategic prosecution decisions. Understanding how the CIPO's "chess clock" philosophy works and implementing key strategies like deferred examination and timely maintenance fee payments can significantly impact whether meaningful term adjustments are granted.
CanadaIntellectual Property
Calfee, Halter & Griswold LLP
Calfee, Halter & Griswold LLP
Article

What Evidence Of Use Is Required In A Section 45 Proceeding?

The Trademarks Opposition Board's recent ruling in Therrien Couture Joli-coeur v Oldcastle Building Products clarifies the evidentiary standards trademark owners must meet when responding to section 45 notices under Canada's Trademarks Act. This decision highlights critical distinctions between evidence of actual transfers versus mere advertising, and underscores the necessity of providing specific proof for each registered good to avoid expungement.
CanadaIntellectual Property
Oyen Wiggs Green & Mutala
Oyen Wiggs Green & Mutala
Article

Restoring Patent Priority In Canada

Canadian patent law provides mechanisms for restoring priority claims when applications are filed after the standard 12-month priority period expires. Understanding the specific requirements, timelines, and criteria for restoration across regular Canadian applications, PCT national phase entries, and international stage PCT applications can help applicants preserve earlier filing dates and avoid self-anticipation issues.
CanadaIntellectual Property
Gowling WLG
Gowling WLG
Article

Trademarks For Businesses - Part 3: Applying To Register A Trademark

Obtaining a trademark registration provides several benefits for businesses. Trademark registrations can help protect your rights and serve as assets that may be leveraged through licensing or used as collateral. However, obtaining a trademark registration in multiple jurisdictions can be a costly endeavour, and it can be difficult to prioritize where and when to seek registration to maximize protection.
CanadaIntellectual Property
Smart & Biggar
Smart & Biggar
Article

A KTEP Ahead: Canada's New Mechanism For Advanced Examination Of Patent Applications

For a Canadian patent application to be examined, an applicant must file a request for examination with the Canadian Intellectual Property Office (CIPO). In most cases, the order in which applications are examined is based on the order that the requests for examination are received. An applicant may be able to accelerate examination of their patent application through several existing mechanisms, including advancing examination via special order, accelerating examination of applications related to green technology, and the Patent Prosecution Highway (PPH).
CanadaIntellectual Property
Smart & Biggar
Smart & Biggar
Article

PMPRB Consults Further On Revised Proposed Practice Directions

The Patented Medicine Prices Review Board (PMPRB) has launched a second 30-day consultation on revised proposed Practice Directions for hearings related to excessive medicine pricing and compliance with filing requirements. The revised directions incorporate feedback from the initial consultation, with a summary chart detailing all edits available for stakeholder review.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

Canada’s Drug Agency: Guidance Document On Use Of AI Methods & Summary Of Precision Medicine Initiatives

Canada's Drug Agency has released new guidance on using artificial intelligence methods to generate real-world evidence for health technology assessments, establishing governance considerations and appraisal principles that emphasize transparency, human oversight, and validation. The agency also launched initiatives supporting precision medicine decision-making, including testing procedure assessments and a pan-Canadian framework for biomarker evaluation in cancer care.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

New Regulatory Amendments Formalize Updates To The Drug And Medical Device Shortages Framework

Health Canada has published comprehensive amendments to drug and medical device shortage regulations, introducing expanded reporting requirements, extended expiration date authorities, and enhanced exceptional importation frameworks. The new measures grant the Minister of Health broader powers to prevent and respond to supply disruptions while requiring manufacturers to provide 12-month advance notice of discontinuations.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

Mise à jour sur les instruments médicaux : modernisation des LEIM, demandes d’homologation d’instruments médicaux de classe III et IV, et rapports sur le rendement de la Direction des instruments médicaux

Santé Canada modernise son processus d'octroi de licences d'établissement d'instruments médicaux avec des modifications réglementaires majeures entrant en vigueur en décembre 2026. Ces changements visent à alléger le fardeau réglementaire, promouvoir l'innovation et améliorer la compétitivité de l'industrie canadienne des dispositifs médicaux.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

Santé Canada obtient une injonction permanente visant à empêcher Canlab Research de vendre illégalement des peptides injectables

Santé Canada a obtenu une injonction permanente contre Canlab Research, interdisant la vente de peptides injectables non autorisés au Canada. Cette décision fait suite à des mesures coercitives répétées visant à protéger les consommateurs contre des produits non homologués présentant des risques graves pour la santé.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar